Bilateral cataracts associated with glucose-6-phosphate dehydrogenase deficiency.

J Perinatol

Faculty of Medicine, Department of Pediatrics, Division of Neonatology, University of Calgary, Calgary, AB, Canada.

Published: July 2013

Glucose-6-phosphate dehydrogenase (G6PD) has an essential role in the defense against cellular oxidative injury. In neonates, the most common manifestation of G6PD deficiency is jaundice and hemolysis due to factors causing oxidative stress. Less known are the ocular associations described with G6PD deficiency, including cataracts. Oxidative injury is involved in the pathogenesis of almost all forms of cataracts, causing the lens proteins to undergo modifications, denaturation and form insoluble aggregates resulting in cataracts. Although cataracts in adult males have been reported in several studies, there are few reports of cataracts in infants with G6PD deficiency. We describe a preterm male neonate with G6PD deficiency who developed bilateral cataracts following an episode of neonatal sepsis and severe hemolysis necessitating an exchange blood transfusion.

Download full-text PDF

Source
http://dx.doi.org/10.1038/jp.2012.148DOI Listing

Publication Analysis

Top Keywords

g6pd deficiency
16
bilateral cataracts
8
glucose-6-phosphate dehydrogenase
8
oxidative injury
8
cataracts
6
deficiency
5
g6pd
5
cataracts associated
4
associated glucose-6-phosphate
4
dehydrogenase deficiency
4

Similar Publications

The medium-fluorescence reticulocyte ratio is an independent predictor of G6PD deficiency neonates.

Int J Hematol

January 2025

Children's Medical Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, People's Republic of China.

Objective: G6PD deficiency is a potentially life-threatening condition in neonates presenting with hyperbilirubinemia. This study aims to identify clinical and laboratory predictors of G6PD deficiency in neonates presenting with hyperbilirubinemia.

Methods: This was a retrospective study of 227 term neonates admitted to Heyuan People's Hospital from January 2019 to October 2023.

View Article and Find Full Text PDF

Quantifying Plasmodium vivax radical cure efficacy: a modelling study integrating clinical trial data and transmission dynamics.

Lancet Infect Dis

January 2025

Institut Pasteur, Université Paris Cité, G5 Épidémiologie et Analyse des Maladies Infectieuses, Paris, France. Electronic address:

Background: Plasmodium vivax forms dormant liver stages (hypnozoites) that can reactivate weeks to months after primary infection. Radical cure requires a combination of antimalarial drugs to kill both the blood-stage and liver-stage parasites. Hypnozoiticidal efficacy of the liver-stage drugs primaquine and tafenoquine cannot be estimated directly because hypnozoites are undetectable.

View Article and Find Full Text PDF

Background: As social media continue to grow as popular and convenient tools for acquiring and disseminating health information, the need to investigate its utilization by laypersons encountering common medical issues becomes increasingly essential.

Objectives: This study aimed to analyze the content posted in Facebook groups for Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency and how these engage the members of the group.

Methods: This study employed an inductive content analysis of user-posted content in both public and private Facebook groups catering specifically to G6PD deficiency.

View Article and Find Full Text PDF

Background: Daily primaquine-induced hemolysis is a common cause of complications during Plasmodium vivax malaria treatment in individuals with glucose 6-phosphate dehydrogenase deficiency (G6PDd). Alternative regimens balancing safety and efficacy are needed.

Methods: G6PDd participants with P.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!